- Home
- Pathway
- Prostacyclin signalling through prostacyclin receptor
description
Prostacyclin (PGI2) is continuously produced by healthy vascular endothelial cells. It inhibits platelet activation through interaction with the Gs-coupled receptor PTGIR, leading to increased cAMP, a consequent increase in cAMP-dependent protein kinase activity which prevents increases of cytoplasmic [Ca2+] necessary for activation (Woulfe et al. 2001). PGI2 is also an effective vasodilator. These effects oppose the effects of thromboxane (TXA2), another eicosanoid, creating a balance of blood circulation and platelet activation
external resources
NCBI:1269342
REACTOME:R-HSA-392851
PUBMED:17164137
genes
GNAS
,
GNB1
,
GNB2
,
GNB3
,
GNG3
,
GNG4
,
GNG5
,
GNG7
,
GNG10
,
GNG11
,
GNGT1
,
GNGT2
,
PTGIR
,
GNB5
,
GNG13
,
GNG2
,
GNG12
,
GNB4
,
GNG8
,